Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 21,010 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Completed Phase 1 Interventional

A Study of L-735,524 in HIV-Positive Children and Adolescents

NCT00002351
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
10 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Whitehouse Station, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

NCT00539695
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorder, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Non-malignant Diseases Requiring Allogeneic HSCT
Interventions
IL-2
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 31, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Results available

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

NCT01062230
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib (Velcade)
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

NCT00472719
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV027-00-VP, VRC-HIVADV038-00-VP, VRC-HIVDNA044-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Acetaminophen Versus Ibuprofen in Children With Asthma

NCT01606319
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Acetaminophen, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 59 Months
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

NCT01996865
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Lenalidomide, Rituximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
110
States / cities
Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 31, 2026, 3:06 PM EDT
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

NCT04603300
View directory record Official record
Conditions
Peanut Allergy
Interventions
INT301, Placebo
Drug
Lead sponsor
Intrommune Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Belleville, New Jersey • Riverdale, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 31, 2026, 3:06 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)

NCT05652907
View directory record Official record
Conditions
Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic
Interventions
FSD201, Placebo
Drug
Lead sponsor
Quantum Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Weldon Spring, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 31, 2026, 3:06 PM EDT
Terminated Phase 1 Interventional

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

NCT00955292
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma
Interventions
Quarfloxin
Drug
Lead sponsor
Cylene Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Not applicable Interventional

The CORRONA Treat to Target Trial: Outcomes and Feasibility in a US Population

NCT01407419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Treatment Acceleration, Monthly Assessment
Other
Lead sponsor
CorEvitas
Network
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 2 Interventional

A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

NCT01007292
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
YM155, Rituximab
Drug · Biological
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Columbus, Georgia • Maywood, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 3 Interventional Results available

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

NCT01520909
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 31, 2026, 3:06 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Nursing Students' Brain/MS Immersive Three-Dimensional Learning Activity

NCT07538063
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
The immersive 360-degree educational video, The slideshow (PowerPoint) educational presentation
Other
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Fairfield, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers

NCT02683863
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
BG00012 (DMF) (Tecfidera®.)
Drug
Lead sponsor
Multiple Sclerosis Center of Northeastern New York
Other
Eligibility
25 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Latham, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Not applicable Interventional Results available

Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System

NCT02797262
View directory record Official record
Conditions
HIV/AIDS, Medication Adherence
Interventions
Proteus digital health feedback (PDHF) system
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
17 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis

NCT01982942
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions
ibudilast, Placebo oral capsule
Drug
Lead sponsor
MediciNova
Industry
Eligibility
21 Years to 65 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 1 Interventional

A Study of Tecogalan Sodium

NCT00002342
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 3:06 PM EDT
Terminated Phase 4 Interventional Results available

Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals

NCT00632970
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Lopinavir/Ritonavir, Truvada
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 31, 2026, 3:06 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Using Mobile Technology to Prevent HIV and Related Youth Health Problems

NCT05130151
View directory record Official record
Conditions
HIV Infections
Interventions
Youth Health SMS
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
15 Years to 19 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 2 Interventional

A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past

NCT00001029
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
35
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 2 Interventional Results available

Study of MAP0010 in Asthmatic Children and Adolescents

NCT00697801
View directory record Official record
Conditions
Asthma
Interventions
MAP0010 low dose, MAP0010 high dose, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
1 Year to 18 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 31, 2026, 3:06 PM EDT
Completed Phase 1 Interventional Results available

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

NCT04128579
View directory record Official record
Conditions
Lupus Erythematosus, Lupus Nephritis
Interventions
Itolizumab [Bmab 600]
Drug
Lead sponsor
Biocon Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Sun City, Arizona • Chula Vista, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 31, 2026, 3:06 PM EDT